Journal article icon

Journal article

Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression

Abstract:
Abstract Background To evaluate the anatomic site(s) of initial disease progression in patients with castration resistant metastatic prostate cancer (mCRPC) in the presence or absence of pre-treatment visceral metastases while on systemic therapy. Methods This is a retrospective cohort study of mCRPC patients who have baseline and at least one follow up bone scan and CT chest, abdomen and pelvis (CAP). Disease progression was determined by RECIST and/or ≥ 30% increase in automated bone scan lesion area score. Kaplan–Meier plot was used to estimate the median progression free survival and log-rank tests were used to compare anatomic sites. Results Of 203 patients, 61 (30%) had pre-treatment visceral metastases. Patients with baseline visceral disease were 1.5 times more likely to develop disease progression (HR = 1.53; 95% CI, 1.03–2.26). Disease progression was a result of worsening bone scan disease (42% (16/38)) versus visceral (32% (12/38)) or lymph node disease (3% (1/38)) by CT or a combination thereof (23% (9/38)). Median time to progression (TTP) did not differ by anatomic location of initial progression (p = 0.86). Development of new lesions occurred in 50% of those visceral patients with soft tissue only progression and was associated with a significantly longer TTP (3.1 months (2.8–4.3 months) than those with worsening of pre-existing lesions (1.8 months (1.6–2.7 months); p = 0.04. Conclusions Patients with pre-treatment visceral metastases in mCRPC are more likely to experience disease progression of bone disease with the initial anatomic site of progression similar to those without baseline visceral involvement
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1186/s40644-022-00469-z

Authors

More by this author
Role:
Author
ORCID:
0000-0001-7988-8484
More by this author
Role:
Author
ORCID:
0000-0003-1225-3489
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-0806-5277
More by this author
Role:
Author
ORCID:
0000-0003-0499-1676
More by this author
Role:
Author
ORCID:
0000-0003-3329-3615


Publisher:
BioMed Central
Journal:
Cancer Imaging More from this journal
Volume:
22
Issue:
1
Pages:
34-34
Article number:
34
Publication date:
2022-07-14
DOI:
EISSN:
1470-7330
ISSN:
1470-7330


Language:
English
Keywords:
Pubs id:
1269511
Local pid:
pubs:1269511
Source identifiers:
W4285386092
Deposit date:
2026-04-27
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP